Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-90
SponsorHawler Medical University

About this trial

Morbid obesity, is known to be associated with a high risk of VTE and, unfortunately, fixed doses of anticoagulant regimens may not provide optimal VTE prophylaxis in these patients especially after surgery.

Eligibility criteria

Qualifiers

Participants required surgical intervention in: general surgery, gynecology, bariatric surgery

Moderate, high, and very high risk for venous thromboembolism according to Caprin RAM

Participant is willing and able to give informed consent for participation in the study.

BMI ≥40kg/m2

Disqualifiers

Having any contraindication to LMWH, such as active bleeding, history of heparin-induced thrombocytopenia , baseline platelet count <75 × 108/μl, severe renal disease (glomerular filtration rate <30 ml/minute), severe liver disease, or uncontrolled hypertension (>200/120 mmHg)

Known hypersensitivity to unfractionated or LMWHs

On oral or parenteral anticoagulants within 5 days before surgery

Severe arterial hypertension

Trial design

Treatments tested in this trial

  • Bemiparin 3500
  • Bemiparin 5000 IU

Treatment groups

2,400 Participants
are divided into 2 treatment groups

Sponsors and collaborators